Akanda (AKAN) Competitors $2.30 +0.09 (+4.12%) As of 10:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKAN vs. GRI, XBIO, GLTO, JAGX, ONCO, APVO, SHPH, SCNI, ENVB, and ADXSShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include GRI Bio (GRI), Xenetic Biosciences (XBIO), Galecto (GLTO), Jaguar Animal Health (JAGX), Onconetix (ONCO), Aptevo Therapeutics (APVO), Shuttle Pharmaceuticals (SHPH), Scinai Immunotherapeutics (SCNI), Enveric Biosciences (ENVB), and Ayala Pharmaceuticals (ADXS). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Its Competitors GRI Bio Xenetic Biosciences Galecto Jaguar Animal Health Onconetix Aptevo Therapeutics Shuttle Pharmaceuticals Scinai Immunotherapeutics Enveric Biosciences Ayala Pharmaceuticals GRI Bio (NASDAQ:GRI) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations. Does the media prefer GRI or AKAN? In the previous week, GRI Bio and GRI Bio both had 2 articles in the media. GRI Bio's average media sentiment score of 0.95 beat Akanda's score of 0.73 indicating that GRI Bio is being referred to more favorably in the media. Company Overall Sentiment GRI Bio Positive Akanda Positive Do institutionals and insiders have more ownership in GRI or AKAN? 34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 0.9% of GRI Bio shares are owned by company insiders. Comparatively, 20.4% of Akanda shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, GRI or AKAN? Akanda has higher revenue and earnings than GRI Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGRI BioN/AN/A-$8.21M-$11.56-0.15Akanda$840K1.26-$4.10MN/AN/A Which has more volatility and risk, GRI or AKAN? GRI Bio has a beta of -1.45, suggesting that its stock price is 245% less volatile than the S&P 500. Comparatively, Akanda has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Do analysts recommend GRI or AKAN? GRI Bio presently has a consensus target price of $22.50, indicating a potential upside of 1,164.04%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Akanda.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Akanda 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GRI or AKAN more profitable? Akanda's return on equity of 0.00% beat GRI Bio's return on equity.Company Net Margins Return on Equity Return on Assets GRI BioN/A -327.62% -191.40% Akanda N/A N/A N/A SummaryAkanda beats GRI Bio on 6 of the 11 factors compared between the two stocks. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.03M$10.52B$6.02B$10.34BDividend YieldN/A1.90%5.73%4.82%P/E RatioN/A20.6084.7826.75Price / Sales1.2628.76598.92130.97Price / CashN/A25.5625.7730.18Price / Book0.253.3612.476.64Net Income-$4.10M$210.63M$3.32B$276.55M7 Day Performance-2.09%-2.24%-0.56%-0.93%1 Month Performance-35.73%-0.15%8.20%6.04%1 Year Performance-63.91%-7.45%75.60%40.02% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkanda1.6342 of 5 stars$2.30+4.1%N/A-66.0%$1.03M$840K0.00110GRIGRI Bio2.3381 of 5 stars$1.97-1.5%$22.50+1,042.1%-73.0%$5.03MN/A0.001XBIOXenetic Biosciences0.7234 of 5 stars$4.29+32.4%N/A+44.4%$5M$2.50M0.004High Trading VolumeGLTOGalecto0.5691 of 5 stars$17.92+383.0%$10.00-44.2%+75.4%$4.91MN/A0.0040High Trading VolumeJAGXJaguar Animal Health2.1653 of 5 stars$2.13-2.7%$60.00+2,716.9%-93.2%$4.76M$11.69M0.0050ONCOOnconetix1.1405 of 5 stars$3.37+9.8%N/A-99.3%$4.75M$2.52M0.0012APVOAptevo Therapeutics1.4809 of 5 stars$1.76+24.8%N/A-100.0%$4.64M$3.11M0.0050Gap UpHigh Trading VolumeSHPHShuttle Pharmaceuticals0.7105 of 5 stars$4.20-2.6%N/A-86.4%$4.61MN/A0.005SCNIScinai Immunotherapeutics1.0249 of 5 stars$1.46+7.7%N/A-64.2%$4.32M$660K0.0020Gap UpHigh Trading VolumeENVBEnveric Biosciences2.1118 of 5 stars$0.70+0.5%$10.00+1,336.2%-89.7%$4.31MN/A0.0020ADXSAyala PharmaceuticalsN/A$0.10flatN/A+23.3%$4.25M$3.24M-0.0120 Related Companies and Tools Related Companies GRI Competitors XBIO Competitors GLTO Competitors JAGX Competitors ONCO Competitors APVO Competitors SHPH Competitors SCNI Competitors ENVB Competitors ADXS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKAN) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
